MCID: PMP014
MIFTS: 48

Pemphigoid

Categories: Immune diseases, Skin diseases

Aliases & Classifications for Pemphigoid

MalaCards integrated aliases for Pemphigoid:

Name: Pemphigoid 12 36 32

Classifications:



External Ids:

Disease Ontology 12 DOID:0080841
KEGG 36 H01650
ICD10 32 L12 L12.9

Summaries for Pemphigoid

KEGG : 36 Pemphigoid diseases are group of autoimmune blistering disorders of the skin and mucous membranes characterized by autoantibodies directed against structural proteins of the dermal-epidermal junction that clinically can manifest with urticarial lesions, tense blisters, and erosions which may involve the mucous membranes. Diseases in this group include bullous pemphigoid (BP), dermatitis herpetiformis, mucous membrane pemphigois, linear IgA bullous dermatosis, herpes gestationis, and epidermolysis bullosa acquisita. BP is the most common acquired bullous autoimmune dermatosis disease. It is primarily a disease of the elderly with an equal incidence in men and women. The clinical characteristics are the formation of tense blisters and pruritic urticarial erythema. Histopathologically, subepidermal blister formation associated with eosinophil infiltration is commonly observed in BP. The main autoantigens targeted by BP autoantibodies are hemidesmosomal transmembrane collagen XVII (COL17, also known as BP180/BPAG2) and the intracytoplasmic plakin family protein BP230. Most of these antibodies belong to the immunoglobulin G class. Diagnosis of BP relies on the clinical and histological aspects, but the most reliable clues are given by direct and indirect immunofluorescence. Three types of drugs, with distinct mechanisms of action, are used to treat BP: anti-inflammatory drugs, drugs designed to reduce the production of pathogenic antibodies, and treatments that increase the elimination of pathogenic antibodies from the serum of patients, such as high-dose intravenous immunoglobulin (IVIG) therapy and therapeutic plasma exchange.

MalaCards based summary : Pemphigoid is related to ocular cicatricial pemphigoid and cicatricial pemphigoid. An important gene associated with Pemphigoid is DST (Dystonin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Hydrocortisone and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and lung, and related phenotypes are digestive/alimentary and hematopoietic system

Disease Ontology : 12 An autoimmune disease of skin and connective tissue that is characterized by subepidermal blistering especially in the lower abdomen, groin, and flexor surfaces of the extremities, creating tense blisters that do not break easily.

Related Diseases for Pemphigoid

Diseases related to Pemphigoid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 826)
# Related Disease Score Top Affiliating Genes
1 ocular cicatricial pemphigoid 32.1 ITGB4 ITGA6 IL4 HLA-DRB1 HLA-DQB1
2 cicatricial pemphigoid 31.9 ITGB4 ITGA6 IL4 HLA-DRB1 HLA-DQB1 DST
3 lichen planus pemphigoides 31.8 ITGB4 DST COL17A1
4 pemphigoid gestationis 31.8 IL5 HLA-DRB1 DST COL17A1 CCL11
5 pemphigus 31.3 TNF IL4 HLA-DRB1 HLA-DQB1 DST COL17A1
6 pemphigus vulgaris, familial 31.3 HLA-DRB1 DST COL17A1
7 epidermolysis bullosa 31.2 ITGB4 ITGA6 DST COL17A1
8 epidermolysis bullosa acquisita 31.1 ITGB4 HLA-DRB1 DST COL17A1
9 linear iga disease 31.0 ITGB4 DST COL17A1
10 pemphigus foliaceus 31.0 HLA-DRB1 DST
11 bullous skin disease 30.7 IL5 DST COL17A1
12 gingivitis 30.6 TNF IL4 IFNG
13 cytokine deficiency 30.5 IL5 IL13
14 pompholyx 30.5 DST COL17A1
15 alopecia 30.4 TNF IL4 IFNG
16 lichen planus 30.4 TNF IL4 IFNG DST COL17A1
17 erythema multiforme 30.4 TNF IL5 IL4 IFNG
18 epidermolysis bullosa, junctional, non-herlitz type 30.4 ITGB4 ITGA6 DST COL17A1
19 epidermolysis bullosa dystrophica 30.4 ITGB4 DST COL17A1
20 junctional epidermolysis bullosa 30.3 ITGB4 ITGA6 DST COL17A1
21 severe cutaneous adverse reaction 30.3 TNF HLA-DRB1 HLA-DQB1
22 subcorneal pustular dermatosis 30.3 DST COL17A1
23 paraneoplastic pemphigus 30.3 HLA-DRB1 HLA-DQB1 DST COL17A1
24 bullous pemphigoid 30.3 TNF ITGB4 ITGA6 IL5 IL4 IL13
25 urticaria 30.2 TNF IL5 IL4 IL13
26 dermatitis herpetiformis 30.2 TNF IL5 IL4 HLA-DQB1 CCL11
27 contact dermatitis 30.1 TNF IL5 IL4 IFNG
28 epidermolysis bullosa simplex 30.1 ITGB4 DST COL17A1
29 stomatitis 30.1 TNF IL4 IFNG
30 purpura 30.0 TNF IL4 IFNG
31 atopic keratoconjunctivitis 30.0 IL5 IL4 IFNG
32 periodontitis 30.0 TNF IL4 IFNG
33 localized scleroderma 29.9 TNF IL4 IL13
34 candidiasis 29.9 TNF IL4 IFNG
35 poliomyelitis 29.9 TNF IL4 IFNG
36 lupus erythematosus 29.9 TNF IFNG HLA-DRB1 HLA-DQB1
37 nocardiosis 29.9 TNF IFNG
38 cutaneous t cell lymphoma 29.9 IL5 IL4 IFNG
39 graft-versus-host disease 29.8 TNF IFNG HLA-DRB1 HLA-DQB1
40 psoriasis 29.8 TNF IL5 IL4 IL13 IFNG HLA-DRB1
41 hypereosinophilic syndrome 29.8 IL5 IL4 IL13 IFNG CCL11
42 herpes zoster 29.8 TNF IFNG HLA-DRB1 COL17A1
43 irritant dermatitis 29.8 TNF IL4
44 chickenpox 29.8 TNF IL4 IFNG
45 silicosis 29.8 TNF IL4 HLA-DQB1
46 pyloric atresia 29.7 ITGB4 ITGA6 COL17A1
47 chronic urticaria 29.7 TNF IL4 IL13
48 measles 29.7 TNF IFNG HLA-DRB1
49 acute graft versus host disease 29.7 TNF IL4 IFNG
50 thyroiditis 29.7 TNF IL4 IFNG HLA-DRB1

Graphical network of the top 20 diseases related to Pemphigoid:



Diseases related to Pemphigoid

Symptoms & Phenotypes for Pemphigoid

MGI Mouse Phenotypes related to Pemphigoid:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.92 HLA-DQB1 IFNG IL13 IL4 IL5 ITGA6
2 hematopoietic system MP:0005397 9.91 CCL11 HLA-DQB1 IFNG IL13 IL4 IL5
3 immune system MP:0005387 9.85 CCL11 HLA-DQB1 IFNG IL13 IL4 IL5
4 integument MP:0010771 9.5 IFNG IL13 IL4 ITGA6 ITGB4 TNF
5 respiratory system MP:0005388 9.32 CCL11 HLA-DQB1 IFNG IL13 IL4 IL5

Drugs & Therapeutics for Pemphigoid

Drugs for Pemphigoid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
2
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
3
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
4
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
5 Vitamins Phase 4
6 Hydrocortisone hemisuccinate Phase 4
7 Hydrocortisone 17-butyrate 21-propionate Phase 4
8 Calciferol Phase 4
9 Calcium, Dietary Phase 4
10 Antineoplastic Agents, Hormonal Phase 4
11 Immunoglobulins, Intravenous Phase 4
12 Immunoglobulin E Phase 4
13
Calcium Nutraceutical Phase 4 7440-70-2 271
14
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
15
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
16
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
17
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
18
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
19
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
20
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
21
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
22
Mycophenolic acid Approved Phase 2, Phase 3 24280-93-1 446541
23
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
24
Dapsone Approved, Investigational Phase 2, Phase 3 80-08-0 2955
25
rituximab Approved Phase 3 174722-31-7 10201696
26
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
27
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
28
Omalizumab Approved, Investigational Phase 3 242138-07-4
29
Benralizumab Approved, Investigational Phase 3 1044511-01-4
30
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
31
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
32
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
33
Cortisone Experimental Phase 2, Phase 3 53-06-5 222786
34 Rho(D) Immune Globulin Phase 3
35 gamma-Globulins Phase 3
36 Alkylating Agents Phase 3
37 Vitamin B9 Phase 2, Phase 3
38 Vitamin B Complex Phase 2, Phase 3
39 Folate Phase 2, Phase 3
40 Gastrointestinal Agents Phase 2, Phase 3
41 Folic Acid Antagonists Phase 2, Phase 3
42 Immunoglobulin A Phase 2, Phase 3
43 Antiemetics Phase 2, Phase 3
44 Antiparasitic Agents Phase 2, Phase 3
45 Triamcinolone diacetate Phase 2, Phase 3
46 Triamcinolone hexacetonide Phase 2, Phase 3
47 Anti-Bacterial Agents Phase 2, Phase 3
48 Antibiotics, Antitubercular Phase 2, Phase 3
49 Neuroprotective Agents Phase 2, Phase 3
50 Methylprednisolone Acetate Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid Unknown status NCT02360202 Phase 4 Clobetasol Propionate cream treatment
2 Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid Unknown status NCT03926377 Phase 4
3 An Open Label Case Series on the Effects of Xolair (Omalizumab) in Bullous Pemphigoid Completed NCT00472030 Phase 4 Omalizumab;prednisone
4 Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid Unknown status NCT02313870 Phase 3 clobetasol propionate + Methotrexate;clobetasol propionate alone
5 Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. Completed NCT02993133 Phase 3 Cellcept® in autoimmune bullous dermatoses
6 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase III) Completed NCT01408550 Phase 3 NPB-01;Placebo
7 Assessment of Rituximab Efficiency and Tolerance in Treatment of Bullous Pemphigoid. Completed NCT00525616 Phase 3 Mabthera
8 Randomized Double Blind Double Dummy Control Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid Recruiting NCT03295383 Phase 3 Rituximab 1g IV;Cyclophosphamide 50Mg Oral Tablet;Placebo of Rituximab;Placebo Oral Tablet
9 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid Recruiting NCT04206553 Phase 2, Phase 3 dupilumab;Matching Placebo;Oral corticosteroids (OCS)
10 Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone Active, not recruiting NCT04744623 Phase 2, Phase 3 large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP
11 An Open-Label Study to Evaluate the Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid Not yet recruiting NCT04128176 Phase 3 Rituximab combined with Omalizumab
12 A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD) Not yet recruiting NCT04612790 Phase 3
13 Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid. An Open Prospective Study Unknown status NCT00802243 Phase 2 leflunomide
14 Anti-IL-5 Therapy in Bullous Pemphigoid. Randomized, Placebo-controlled, Double-blind Study Evaluating the Effect of Anti-IL-5 Therapy in Patients With Bullous Pemphigoid. Completed NCT01705795 Phase 2 Mepolizumab (a-IL-5 antibody);Placebo
15 The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
16 Phase I/II Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid Completed NCT00584935 Phase 1, Phase 2 Rituximab
17 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(PhaseⅡ). Completed NCT00809822 Phase 2 NPB-01;Placebo
18 A Phase IIa Open-label Single Arm Study of Safety and Efficacy of rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects Completed NCT04035733 Phase 2
19 A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid Completed NCT00431119 Phase 2 Azathioprine or Mycophenolate mofetil
20 An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid Completed NCT02226146 Phase 2
21 Rituximab in the Treatment of Patients With Bullous Pemphigoid Completed NCT00286325 Phase 1, Phase 2 Rituximab
22 Ixekizumab in the Treatment of Bullous Pemphigoid Completed NCT03099538 Phase 2 Ixekizumab
23 Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Inflammatory Ulcerative Diseases Recruiting NCT04540133 Phase 2 dexamethasone 0.5mg/5ml solution;dexamethasone 0.5mg/5ml solution in Mucolox™
24 Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody Recruiting NCT04563923 Phase 2 Avdoralimab (IPH5401)
25 Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid Recruiting NCT04499235 Phase 2 Mometasone furoate;AKST4290;Placebo
26 Efficacy and Safety of Ustekinumab in Bullous Pemphigoid Recruiting NCT04117932 Phase 2 Ustekinumab
27 A Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Bullous Pemphigoid With Disease Refractory to Oral Steroid Treatment Terminated NCT01688882 Phase 2 QGE031;Placebo
28 A Phase 2, Multicentre, Single Arm, Pilot Study to Assess the Efficacy and the Safety of 150 mg Twice a Day Oral DF2156A in Patients With Active Bullous Pemphigoid. Terminated NCT01571895 Phase 2 DF2156A
29 A Randomized, Open-Label, Controlled Trial of Topical AC-203 in Subjects With Bullous Pemphigoid Terminated NCT03286582 Phase 2 AC-203 1% Topical Ointment;Clobetasol 0.05% Topical Ointment
30 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
31 The Improvement of Limbal Epithelial Culture Technique for the Treatment of Unilateral Limbal Insufficiency by Using Collagenase to Isolate Limbal Stem Cells Unknown status NCT02202642 Phase 1
32 Phase I Study of Vorinostat in Combination With Niacinamide, and Etoposide for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies Completed NCT00691210 Phase 1 Vorinostat;Niacinamide;Etoposide
33 Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study. Active, not recruiting NCT02502903 Phase 1 BIV009
34 Serum Free Fatty Acids Desaturase Activity Indices in Sera of Patients on Long-term High-dose Corticosteroid Treatment Unknown status NCT02872584 Prednisone
35 Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? : Multicenter Retrospective Study in France and Switzerland Unknown status NCT03636763 data report
36 Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission Unknown status NCT01265082
37 Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid Unknown status NCT02874079
38 Multicenter Prospective Observational Study Assessing Outcomes, Adverse Events, Treatment Patterns and Related Costs in Patients Diagnosed With Bullous Pemphigoid Unknown status NCT02837965 treatment with topical superpotent corticosteroid therapy;treatment with systemic therapy (methotrexate);treatment systemic therapy (prednisone);treatment with systemic therapy (prednisone);treatment with systemic therapy (doxycycline)
39 An Open Randomized Comparative Trial of Four Different Dressings for Cutaneous Coverage in Pemphigus and Pemphigoid Unknown status NCT02365675
40 Pruritus and Pemphigoid in Nursing Home Patients Completed NCT02823067
41 Evaluation of Cytokines and Immunoglobulins in Serum and Blister Fluids Appeared Before Treatment and Subsequently Under Treatment in Bullous Pemphigoid Completed NCT03856840
42 Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients Completed NCT03320798
43 Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid Completed NCT02883894
44 Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus Completed NCT00213421 Dermoval
45 Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid Completed NCT03272958
46 Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface Recruiting NCT04198740
47 The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Recruiting NCT03839069
48 Clinical, Biological and Histological Characteristics of Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy: A National Retrospective Cohort Study Recruiting NCT04641884
49 Prevalence and Clinical Severity of Autoimmune Blistering Diseases Recruiting NCT02753777
50 The Association of Bullous Pemphigoid With Dipeptidyl-peptidase 4 Inhibitors: Α Ten-year Prospective Observational Study. Active, not recruiting NCT04469582

Search NIH Clinical Center for Pemphigoid

Genetic Tests for Pemphigoid

Anatomical Context for Pemphigoid

MalaCards organs/tissues related to Pemphigoid:

40
Skin, Eye, Lung, T Cells, Bone, Kidney, Neutrophil

Publications for Pemphigoid

Articles related to Pemphigoid:

(show top 50) (show all 6867)
# Title Authors PMID Year
1
Chronic Systemic Inflammatory Skin Disease as a Risk Factor for Cardiovascular Disease. 61
33607473 2021
2
[Paraneoplastic autoimmune dermatoses]. 61
33646324 2021
3
Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report. 61
33811313 2021
4
Case of bullous pemphigoid under treatment with adalimumab for hidradenitis suppurativa. 61
33502014 2021
5
Clinical characteristics and outcomes of bullous pemphigoid patients with versus without oral prednisolone treatment. 61
33600037 2021
6
Case of bullous pemphigoid induced by apatinib mesylate. 61
33534135 2021
7
Evaluation of BP180-NC16A ELISA in exclusive oral pemphigoid diagnosis. A comparative study. 61
32726466 2021
8
Patients with bullous pemphigoid and comorbid psoriasis present with less blisters and lower serum levels of anti-BP180 autoantibodies. 61
33098720 2021
9
A case of non-bullous pemphigoid induced by IgG4 autoantibodies targeting BP230. 61
33219610 2021
10
IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients. 61
33058320 2021
11
Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: A comparative study of 100 patients with bullous pemphigoid and diabetes mellitus. 61
33543537 2021
12
Laryngeal mucous membrane pemphigoid serves as a prognostic factor for poor response to treatment with rituximab. 61
33811681 2021
13
Serologic characterization of anti-p200 pemphigoid: Epitope spreading as a common phenomenon. 61
32711089 2021
14
Bullous eczema presenting as bullous pemphigoid-like eruption: A case series. 61
33732844 2021
15
Blockade of complement activation in bullous pemphigoid by using recombinant CD55-CD46 fusion protein. 61
33797471 2021
16
Clinical and immunological findings in 55 cases of anti-laminin-332-type mucous membrane pemphigoid. 61
33811327 2021
17
Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature. 61
32772795 2021
18
Real-world experience of using ciclosporin-A 0.1% (Ikervis) in the management of ocular surface inflammatory diseases. 61
33687999 2021
19
The micronucleus cytome assay - A fast tool for DNA damage screening in human conjunctival epithelial cells. 61
33677062 2021
20
The role of Dipeptidyl Peptidase-4 in cutaneous disease. 61
33131073 2021
21
Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity. 61
33686442 2021
22
Refractory bullous pemphigoid with IgE anti-BP230 and IgG anti-p200 antibodies successfully treated with omalizumab. 61
33478824 2021
23
Mixed Individual-Aggregate Data on All-Cause Mortality in Bullous Pemphigoid: A Meta-analysis. 61
33729430 2021
24
How to diagnose bullous pemphigoid and its variants: the question is still open. 61
33660331 2021
25
Crossreactivity: The possible role of oral microbiota in oral mucous membrane pemphigoid. 61
33722751 2021
26
Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials. 61
32741073 2021
27
A case of mucous membrane pemphigoid with anti-BP230 autoantibodies alone. 61
32970829 2021
28
A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor. 61
32634333 2021
29
Diagnostic Value and Practicability of Serration Pattern Analysis by Direct Immunofluorescence Microscopy in Pemphigoid Diseases. 61
33491096 2021
30
Response to Letter to the editor of Borradori et al. How to diagnose bullous pemphigoid and its variants: the question is still open. 61
33657256 2021
31
Immunomodulator Galectin-9 is Increased in Blood and Skin of Patients with Bullous Pemphigoid. 61
33606034 2021
32
Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study. 61
33783881 2021
33
Tissue eosinophil levels as a marker of disease severity in bullous pemphigoid. 61
33748980 2021
34
Pancreatic Acinar Cell Carcinoma with Concomitant Bullous Pemphigoid. 61
33757939 2021
35
Risk of solid malignancies in bullous pemphigoid: A large-scale population-based cohort study. 61
33368562 2021
36
Lichen planus-like lesion preceding bullous pemphigoid development after programmed cell death protein-1 inhibitor treatment. 61
33184934 2021
37
A case of dipeptidyl-peptidase 4 inhibitor-associated pemphigoid nodularis. 61
33660842 2021
38
Efficacy and safety of tetracyclines for pemphigoid: a systematic review and meta-analysis. 61
33774726 2021
39
Differences in the Clinical Presentation of Bullous Pemphigoid in Skin of Color and White Patients. 61
33735455 2021
40
PD-L1 positive macrophages were increased in a case of pembrolizumab-induced bullous pemphigoid. 61
33439513 2021
41
Mortality and clinical response of patients with bullous pemphigoid treated with rituximab. 61
33657641 2021
42
Pseudosyndactyly and digital contractures in bullous pemphigoid with anti-BP180-C-terminal domain autoantibodies. 61
33715202 2021
43
Melanoma is associated with an increased risk of bullous pemphigoid: a large population-based longitudinal study. 61
33687539 2021
44
Infantile bullous pemphigoid following serogroup B meningococcal vaccination. 61
32892343 2021
45
Autoantibody Detection for Diagnosis in Direct Immunofluorescence-Negative Mucous Membrane Pemphigoid: Ocular and Other Sites Compared. 61
32745569 2021
46
Disease Relapse After Drug-Free Remission in Ocular Mucous Membrane Pemphigoid. 61
32976845 2021
47
Onset of acquired haemophilia A after omalizumab treatment in severe bullous pemphigoid - a report on two cases successfully treated with mycophenolate mofetil. 61
33461795 2021
48
Pemphigus and Bullous Pemphigoid in the United States: A 21-year Analysis of Patient Characteristics, Treatment Patterns, and Comorbidities. 61
33769922 2021
49
Two Cases of Porokeratosis with MVD Mutations, in Association with Bullous Pemphigoid. 61
33554266 2021
50
Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities. 61
33725360 2021

Variations for Pemphigoid

Expression for Pemphigoid

Search GEO for disease gene expression data for Pemphigoid.

Pathways for Pemphigoid

Pathways related to Pemphigoid according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 ZAP70 TNF IL5 IL4 IL13 IFNG
2
Show member pathways
13.72 ZAP70 TNF ITGB4 ITGA6 IL5 IL4
3
Show member pathways
13.46 TNF ITGB4 ITGA6 IL5 IL4 IL13
4
Show member pathways
13.32 ZAP70 TNF ITGB4 ITGA6 IL5 IL4
5
Show member pathways
13.27 TNF IL5 IL4 IL13 IFNG HLA-DRB1
6 12.78 ITGA6 IL5 IL4 IL13 IFNG
7
Show member pathways
12.71 TNF IL5 IL4 IL13 IFNG HLA-DRB1
8
Show member pathways
12.66 ITGB4 ITGA6 DST COL17A1
9
Show member pathways
12.61 ITGB4 ITGA6 DST COL17A1
10
Show member pathways
12.58 ZAP70 TNF IL5 IL4 IFNG
11
Show member pathways
12.57 ZAP70 TNF IL4 IFNG HLA-DRB1 HLA-DQB1
12
Show member pathways
12.51 TNF IL5 IL4 IL13
13 12.49 ZAP70 TNF IL4 IFNG
14
Show member pathways
12.45 ZAP70 TNF IL4 IFNG
15
Show member pathways
12.36 IL5 IL4 IL13 IFNG
16
Show member pathways
12.31 TNF IL5 IL4 IL13 IFNG CCL11
17
Show member pathways
12.24 TNF IL5 IL4 IL13 IFNG
18
Show member pathways
12.21 TNF ITGA6 IL4 IFNG HLA-DRB1 HLA-DQB1
19 12.2 TNF IFNG HLA-DRB1 HLA-DQB1
20
Show member pathways
12.16 TNF IL4 IFNG CCL11
21
Show member pathways
12.1 ZAP70 TNF IL5 IL4 IL13 IFNG
22 12.04 ITGA6 HLA-DRB1 HLA-DQB1
23 11.98 TNF IL5 IL4 IFNG
24 11.96 TNF IL4 IL13 CCL11
25 11.95 TNF IL4 IFNG
26
Show member pathways
11.92 IL4 IFNG HLA-DRB1
27
Show member pathways
11.9 ZAP70 HLA-DRB1 HLA-DQB1
28 11.88 ZAP70 ITGB4 ITGA6
29 11.86 ZAP70 HLA-DRB1 HLA-DQB1
30 11.86 TNF IFNG HLA-DRB1 HLA-DQB1
31 11.8 IL5 IL4 IL13 IFNG
32 11.78 TNF IL5 IL4 IL13 IFNG
33
Show member pathways
11.75 TNF IL5 IL4 IFNG
34 11.73 TNF ITGA6 IL5 IL4 HLA-DRB1 HLA-DQB1
35 11.7 ZAP70 HLA-DRB1 HLA-DQB1
36 11.66 TNF IL5 IL4
37 11.63 IL5 IL4 CCL11
38 11.63 TNF IL5 IL4 IL13 CCL11
39 11.52 TNF IL4 IL13
40 11.38 IL5 IL4 IL13 IFNG CCL11
41 11.34 ZAP70 IL5 IL4 IFNG
42 11.3 ITGB4 ITGA6 COL17A1
43 11.24 IL13 IFNG HLA-DRB1
44 11.23 IL5 IL4 IL13 IFNG
45 11.06 TNF IL5 IL4 IL13 IFNG
47 10.91 TNF ITGB4 ITGA6 IL5 IL4 IL13
48 10.8 IL5 IL4 IL13
49 10.56 TNF IL5 IL4 IL13 IFNG HLA-DRB1

GO Terms for Pemphigoid

Cellular components related to Pemphigoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 TNF IL5 IL4 IL13 IFNG HLA-DRB1
2 basement membrane GO:0005604 9.33 ITGB4 DST COL17A1
3 MHC class II protein complex GO:0042613 9.26 HLA-DRB1 HLA-DQB1
4 hemidesmosome GO:0030056 8.8 ITGB4 DST COL17A1

Biological processes related to Pemphigoid according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.95 TNF IL5 IL13 CCL11
2 extracellular matrix organization GO:0030198 9.88 TNF ITGB4 ITGA6 COL17A1
3 response to virus GO:0009615 9.81 TNF IFNG CCL11
4 integrin-mediated signaling pathway GO:0007229 9.79 ITGB4 ITGA6 DST
5 interferon-gamma-mediated signaling pathway GO:0060333 9.74 IFNG HLA-DRB1 HLA-DQB1
6 cytokine-mediated signaling pathway GO:0019221 9.72 TNF IL5 IL4 IL13 CCL11
7 positive regulation of B cell proliferation GO:0030890 9.67 IL5 IL4 IL13
8 macrophage differentiation GO:0030225 9.66 IFNG HLA-DRB1
9 positive regulation of amyloid-beta formation GO:1902004 9.66 TNF IFNG
10 positive regulation of T cell differentiation GO:0045582 9.65 ZAP70 IL4
11 positive regulation of immunoglobulin production GO:0002639 9.65 IL5 IL13
12 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.64 TNF IFNG
13 astrocyte activation GO:0048143 9.64 TNF IFNG
14 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.63 HLA-DRB1 HLA-DQB1
15 macrophage activation GO:0042116 9.62 IL4 IL13
16 negative regulation of amyloid-beta clearance GO:1900222 9.61 TNF IFNG
17 positive regulation of podosome assembly GO:0071803 9.61 TNF IL5
18 positive regulation of MHC class II biosynthetic process GO:0045348 9.6 IL4 IFNG
19 skin morphogenesis GO:0043589 9.59 ITGB4 ITGA6
20 positive regulation of mast cell degranulation GO:0043306 9.58 IL4 IL13
21 nail development GO:0035878 9.56 ITGB4 ITGA6
22 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.56 TNF IL4 IL13 IFNG
23 positive regulation of mononuclear cell migration GO:0071677 9.55 TNF IL4
24 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.54 HLA-DRB1 HLA-DQB1
25 positive regulation of cellular respiration GO:1901857 9.52 IL4 IFNG
26 neuroinflammatory response GO:0150076 9.51 IL4 IFNG
27 negative regulation of complement-dependent cytotoxicity GO:1903660 9.48 IL4 IL13
28 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.46 TNF IFNG
29 microglial cell activation GO:0001774 9.46 TNF IL4 IL13 IFNG
30 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.43 HLA-DRB1 HLA-DQB1
31 positive regulation of vitamin D biosynthetic process GO:0060557 9.4 TNF IFNG
32 positive regulation of nitrogen compound metabolic process GO:0051173 9.37 TNF IFNG
33 immune response GO:0006955 9.28 ZAP70 TNF IL5 IL4 IL13 IFNG
34 hemidesmosome assembly GO:0031581 9.26 ITGB4 ITGA6 DST COL17A1

Molecular functions related to Pemphigoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor I binding GO:0031994 9.26 ITGB4 ITGA6
2 MHC class II receptor activity GO:0032395 9.16 HLA-DRB1 HLA-DQB1
3 cytokine activity GO:0005125 9.1 TNF IL5 IL4 IL13 IFNG CCL11
4 neuregulin binding GO:0038132 8.96 ITGB4 ITGA6

Sources for Pemphigoid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....